EdiGene Approved to Start China Trial of Gene-Edited Stem Cell Therapy

EdiGene, a Beijing company, was approved to start China clinical trials of ET-01, its gene-edited stem cell therapy, to treat transfusion dependent β-thalassemia. Thalassemia is a group of blood diseases characterized by decreased or absent synthesis of normal globin chains. Patients with transfusion dependent forms of the disease require regular transfusions to live. EdiGene said the NMPA approval was the first gene-editing therapy and the first hematopoietic stem cell therapy IND application approved in China . More details.... Share this with colleagues: // //